rituximab,obinutuzumab
biogen,roche
['obinu']
gallium trial: minimal or no role for obinutuzumab in fl , although pfs and ttnt benefit , absence of os benefit in long follow up. pfs is not a surrogate end point in fl. #eha2022 
MD. Hematology and Hematopoietic Stem Cell Transplantation. Hospital Universitário Antônio Pedro (HUAP-UFF)